Controversies in the adjuvant therapy of high-grade gliomas.

  title={Controversies in the adjuvant therapy of high-grade gliomas.},
  author={Matthias Holdhoff and Stuart Grossman},
  journal={The oncologist},
  volume={16 3},
The 2-year survival rate of patients with glioblastoma accrued to research studies increased from 10% to nearly 40% from 2000 to 2010. These improvements began with the demonstration of a survival benefit when daily temozolomide was administered with 6 weeks of standard radiation and for 6 months thereafter. This treatment regimen is often associated with significant lymphopenia, thrombocytopenia, and progressive blood-brain barrier dysfunction that can result in clinical and radiologic… CONTINUE READING